Nectar Lifesciences FY26 Net Loss ₹292.89 Crore

Total Income: ₹9.29 crore (Previous Year ₹1.88 crore)
Total Expenses: ₹971.61 crore (Previous Year ₹0.81 crore)
Loss before tax from continuing operations: ₹(878.70) crore
Profit from discontinued operations (after exceptional item): ₹(235.54) crore
Net Loss for the period: ₹(292.88) crore (Previous Year Net Loss ₹(113.68) crore)
Basic & Diluted EPS (continuing & discontinued): ₹(13.40) (Previous Year ₹(5.07))

Total Income: ₹9.29 crore
Total Expenses: ₹971.70 crore
Loss before tax from continuing operations: ₹(878.79) crore
Profit from discontinued operations (after exceptional item): ₹(235.54) crore
Net Loss for the period: ₹(292.89) crore
Basic & Diluted EPS (continuing & discontinued): ₹(13.40)

Total Assets: ₹612.34 crore (Previous Year ₹2,047.23 crore)
Cash and cash equivalents: ₹108.13 crore (Previous Year ₹19.22 crore)
Total Equity: ₹582.31 crore (Previous Year ₹956.11 crore)
Paid-up equity share capital: ₹19.43 crore (reduced from ₹22.43 crore due to buyback)

Board Meeting: May 30, 2026 (commenced 12:30 PM, concluded 2:20 PM IST)
Financial Year End: March 31, 2026
Re-appointment of Independent Directors: Dr. Kuldip Kumar Bhasin effective September 21, 2026; Dr. Indu Pal Kaur effective August 02, 2027 (subject to AGM approval)
Buy-back period: December 31, 2025 to January 06, 2026
Slump sale completion: November 10, 2025
Acquisition of AEPL: Effective March 6, 2026

Statutory Auditors: Deepak Jindal & Co.
Registrar and Transfer Agent (RTA): KFin Technologies Limited (continuation confirmed)
Buy-back counterparty: Eligible equity shareholders (excluding Promoters and Promoter Group)
Pharma Business Buyer: Ceph Lifesciences Private Limited
Capsule Business Proposed Buyer: Capnest Health Care Private Limited
Wholly-owned Subsidiaries: Avensis Exports Private Limited (AEPL), Neclife PT, Unipessoal LDA (inoperative)

The results disclosure is a regulatory requirement under SEBI LODR Regulations.
The slump sale of the Pharma Businesses was undertaken to generate liquidity and optimize the business portfolio.
The buy-back was implemented to return value to shareholders.
The acquisition of AEPL and amendment of the object clause to include real estate activities are part of a strategic shift in business focus.

The disposal of the Pharma Businesses and Menthol Assets has fundamentally altered the company's operations and financial profile:

Consideration Received: ₹1,273.99 crore (₹1,187.99 crore received, ₹66.00 crore receivable)
Gain on Slump Sale Recognized: ₹163.37 crore (exceptional item)
Resulting Impact: Reported as discontinued operations, contributing a net loss of ₹235.54 crore for FY26 after tax.

Share Buy-back: 3,00,00,000 equity shares (₹1 each) bought back at ₹27 per share, totaling ₹81.00 crore.
Capital Reduction: Paid-up equity share capital reduced by ₹3.00 crore.
Reserves Impact: ₹78.00 crore adjusted against Securities Premium Account; ₹3.00 crore transferred to Capital Redemption Reserve.

A loss of ₹52.10 crore was recognized on investments in mutual funds, ETFs, and equity instruments due to market volatility.

The company states it possesses "adequate cash and liquid resources" (₹108.13 crore cash) after discharging all debts from the slump sale proceeds.

Re-appointment of Independent Directors: Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur proposed for second terms of five years each, subject to AGM approval.
RTA: Withdrew proposal to appoint Alankit Assignments Limited; KFin Technologies Limited continues as RTA.
Policy Amendments: Materiality of Information Policy, Related Party Transaction Policy, and Code of Conduct for Prevention of Insider Trading updated to align with amended LODR Regulations.
KMP Authorization: Mr. Sushil Kapoor (Whole Time Director & CFO) authorized for determining materiality; Mr. Sanjaymohan Singh Rawat (Compliance Officer) for making disclosures to exchanges.

The auditors drew attention to three key notes in their report:

1. Note 9: The company's assessment of its ability to continue as a going concern, following the slump sale and significant losses.

2. Note 10: The significant transactions/events during the year, including the slump sale and their consequential financial impacts.

3. Note 12: The company incurring a substantial loss of ₹52.10 crore on investments.

The auditors' opinion was not modified regarding these matters.

The Board believes the company will continue as a going concern due to its solvent financial position and available funds.
The company is evaluating various projects in the real estate sector under its revised business framework.
The company is evaluating the monetization of non-core assets (Jammu Unit fixed assets, land near Garhshankar) to optimize assets and strengthen liquidity.
The slump sale of the Capsule Business to Capnest Health Care is pending completion per the agreed terms and regulatory approval.